Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 9, 2010, Pages 1135-1144

  Oussalah, A ^a   Laurent, V ^a   Bruot, O ^a   Gueant J L ^b   Regent D ^a   Bigard, M A ^a   Peyrin Biroulet, L ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; GADOLINIUM; MESALAZINE; METHOTREXATE; PROCALCITONIN; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; INFLAMMATION; MAGNETIC RESONANCE COLONOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SERUM;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CROHN DISEASE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 78649478490     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04459.x     Document Type: Article

References (22)

1. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol 2010; 159: 253-64.
2. Liappis AP, Gibbs KW, Yoon B, et al. Human leukocyte and whole blood cytokine response to exogenous procalcitonin. The 89th Endocrine Society Meeting. Toronto, Canada, June 2007 [Abstract P1-367].
3. Whang KT, Vath SD, Becker KL, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock 2000; 14: 73-8.
4. Redl H, Schiesser A, Togel E, Assicot M, Bohuon C. Possible role of TNF on procalcitonin release in a baboon model of sepsis. Shock 2001; 16: 25-7.
5. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206-17.
6. Moosig F, Csernok E, Reinhold-Keller E, Schmitt W, Gross WL. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol 1998; 25: 1531-3.
7. Korczowski B, Kowalczyk JR, Bijak M, Rusin J. Concentration of procalcitonin and C-reactive protein in serum and erythrocyte sedimentation rate in active autoimmune diseases in children. Pol Merkur Lekarski 2003; 15: 155-7.
8. Quintana G, Medina YF, Rojas C, et al. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheumatol 2008; 14: 138-42.
9. Herrlinger KR, Dittmann R, Weitz G, et al. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. Inflamm Bowel Dis 2004; 10: 229-33.
10. Thia KT, Chan ES, Ling KL, Ng WY, Jacob E, Ooi CJ. Role of procalcitonin in infectious gastroenteritis and inflammatory bowel disease. Dig Dis Sci 2008; 53: 2960-8.
11. Oruc N, Ozutemiz O, Osmanoglu N, Ilter T. Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease. Turk J Gastroenterol 2009; 20: 9-12.
12. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43: 29-32.
13. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
14. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979; 77(4 Pt2): 843-6.
15. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4-beta7 integrin. N Eng J Med 2005; 352: 2499-507.
16. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12.
17. Oussalah A, Laurent V, Bruot O, et al. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut 2010; 59: 1056-65.
18. Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol 2003; 38: 164-71.
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
20. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 1188-97.
21. Higgins PD, Leung J, Schwartz M, Mapili J, Wren PA, Zimmermann EM. The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis. Aliment Pharmacol Ther 2007; 25:333-42.
22. Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1081-8.